Geron Stock (NASDAQ:GERN)
Previous Close
$3.66
52W Range
$1.64 - $5.34
50D Avg
$4.04
200D Avg
$4.07
Market Cap
$2.11B
Avg Vol (3M)
$8.06M
Beta
0.52
Div Yield
-
GERN Company Profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
GERN Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
Quarter
| Product/Service | Sep 24 |
|---|---|
| Chargeback And Distributor Service Fees | $-4.00M |
| Government Rebates | $-364.00K |
| Product | $28.21M |
| Revenues Before Adjustments | $32.66M |
| Sales Returns And Allowance | $-82.00K |
| Total Gross To Net Adjustments | $-4.45M |
Latest
Fiscal year ends in Dec 23 | Currency in USD
Peer Comparison
| Ticker | Company |
|---|---|
| TGTX | TG Therapeutics, Inc. |
| PTCT | PTC Therapeutics, Inc. |
| PDSB | PDS Biotechnology Corporation |
| VKTX | Viking Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| SRPT | Sarepta Therapeutics, Inc. |
| IMMX | Immix Biopharma, Inc. |
| ZURA | Zura Bio Limited |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| ELEV | Elevation Oncology, Inc. |
| OCEA | Ocean Biomedical, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |
| ENVB | Enveric Biosciences, Inc. |